<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006342.pub2" GROUP_ID="PVD" ID="700706070410481816" MERGED_FROM="" MODIFIED="2015-01-12 08:50:24 +0000" MODIFIED_BY="Marlene Stewart" REVIEW_NO="1121" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2015-01-12 08:50:24 +0000" MODIFIED_BY="Marlene Stewart">
<TITLE MODIFIED="2015-01-09 11:47:18 +0000" MODIFIED_BY="[Empty name]">Beta-adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery</TITLE>
<CONTACT MODIFIED="2015-01-12 08:50:24 +0000" MODIFIED_BY="Marlene Stewart"><PERSON ID="101C96DC82E26AA20003EB8A68141294" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katayoun</FIRST_NAME><LAST_NAME>Mostafaie</LAST_NAME><POSITION>Associate Professor of Medicine</POSITION><EMAIL_1>Kkmostafaie@yahoo.com</EMAIL_1><EMAIL_2>kmostafaie@dhs.lacounty.gov</EMAIL_2><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>David Geffen School of Medicine at UCLA</ORGANISATION><ADDRESS_1>1000 West Carson</ADDRESS_1><CITY>Torrance</CITY><ZIP>92604</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 310 2228157</PHONE_1><FAX_1>+1 310 3286837</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-01-12 08:50:24 +0000" MODIFIED_BY="Marlene Stewart"><PERSON ID="101C96DC82E26AA20003EB8A68141294" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katayoun</FIRST_NAME><LAST_NAME>Mostafaie</LAST_NAME><POSITION>Associate Professor of Medicine</POSITION><EMAIL_1>Kkmostafaie@yahoo.com</EMAIL_1><EMAIL_2>kmostafaie@dhs.lacounty.gov</EMAIL_2><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>David Geffen School of Medicine at UCLA</ORGANISATION><ADDRESS_1>1000 West Carson</ADDRESS_1><CITY>Torrance</CITY><ZIP>92604</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 310 2228157</PHONE_1><FAX_1>+1 310 3286837</FAX_1></ADDRESS></PERSON><PERSON ID="z1308221148098966495610632139453" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Rachel</FIRST_NAME><LAST_NAME>Bedenis</LAST_NAME><EMAIL_1>rbedenis@gmail.com</EMAIL_1><EMAIL_2>rbedenis@staffmail.ed.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Population Health Sciences</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><CITY>Edinburgh</CITY><ZIP>EH8 9AG</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="38B6927882E26AA20003EB8A5B67D63A" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Darrell</FIRST_NAME><LAST_NAME>Harrington</LAST_NAME><EMAIL_1>dharrington@dhs.lacounty.gov</EMAIL_1><ADDRESS><ORGANISATION>David Geffen School of Medicine at UCLA</ORGANISATION><CITY>Los Angeles</CITY><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 310 222 2903</PHONE_1><FAX_1>+1 310 328 6837</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-10-14 12:44:03 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="20" MONTH="1" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="1" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="1" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2015"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2012-11-04 12:05:39 +0000" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2012-11-04 12:05:39 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-11-04 12:05:39 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-01-09 10:57:27 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-01-09 10:57:27 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-01-09 10:57:27 +0000" MODIFIED_BY="[Empty name]">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-01-11 16:21:18 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-01-11 16:21:18 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-01-09 11:48:17 +0000" MODIFIED_BY="[Empty name]">Beta-blockers for cardiac risk reduction in people undergoing non-cardiac vascular surgery</TITLE>
<SUMMARY_BODY MODIFIED="2015-01-11 16:21:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>As the population is ageing, more people will undergo major vascular surgery, which carries an increased risk of cardiac complications. The increased risk of cardiac complications is often the result of asymptomatic heart disease. Treating severe symptoms, such as critical limb ischaemia (severely narrowed arteries of the lower limbs resulting in rest pain, ulcers, or gangrene), in people with peripheral arterial disease is a common reason for undergoing vascular surgery, which carries an increased risk heart attack (myocardial infarction) ranging from 5% to 24% during and shortly after surgery. There is clear evidence for the use of beta-blockers (a class of medications used to treat certain heart conditions as well as high-blood pressure and other conditions) to reduce cardiac risk in people with known heart disease, and it has been suggested that beta-blockers may reduce short-term cardiac illness (morbidity) and death (mortality) in people undergoing major non-cardiac vascular surgery.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We identified two studies that evaluated beta-blockers giving during surgery (perioperatively) in people undergoing major non-cardiac vascular surgery, with follow-up data on cardiovascular outcomes. A total of 599 participants were randomised to receive beta-blockers (301 participants) or placebo (298 participants). Both studies were double-blind (neither participants nor surgeon were aware of the treatment), randomised controlled trials evaluating the beta-blocker, metoprolol.</P>
<P>
<B>Key results</B>
</P>
<P>The results of the analysis offered no clear evidence that perioperative beta-blockers reduced death from any cause (all-cause mortality), cardiovascular death, non-fatal heart attack, irregular heartbeat (arrhythmia), heart failure, stroke, combined cardiovascular events or re-hospitalisation at 30 days. There was evidence to support that beta-blockers increased the risk of intra-operative low heart rate (bradycardia) and low blood pressure (hypotension). These complications should be weighed with any benefit when considering the use of beta-blockers in this population.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Study quality was good for both trials. One trial did not adequately describe their randomisation techniques and the other trial did not report whether the outcome assessors were blinded to the treatment group, and was possibly underpowered. With only two studies included, several of the outcomes only had data from a single study, and neither of the studies reported on blockage or obstruction of blood vessels (vascular patency/graft occlusion), reducing the quality of evidence to moderate.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-01-09 11:48:16 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-01-09 11:47:31 +0000" MODIFIED_BY="[Empty name]">
<P>People undergoing major vascular surgery have an increased risk of postoperative cardiac complications. Beta-adrenergic blockers represent an important and established pharmacological intervention in the prevention of cardiac complications in people with coronary artery disease. It has been proposed that this class of drugs may reduce the risk of perioperative cardiac complications in people undergoing major non-cardiac vascular surgery.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-01-09 11:47:32 +0000" MODIFIED_BY="[Empty name]">
<P>To review the efficacy and safety of perioperative beta-adrenergic blockade in reducing cardiac or all-cause mortality, myocardial infarction, and other cardiovascular safety outcomes in people undergoing major non-cardiac vascular surgery.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-01-09 11:47:42 +0000" MODIFIED_BY="[Empty name]">
<P>The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (January 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2013, Issue 12). We searched trials databases and checked reference lists of relevant articles.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-01-09 11:47:46 +0000" MODIFIED_BY="[Empty name]">
<P>We included prospective, randomised controlled trials of perioperative beta-adrenergic blockade of people over 18 years of age undergoing non-cardiac vascular surgery.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-01-09 11:47:50 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently performed study selection and data extraction. We resolved disagreements through discussion. We performed meta-analysis using a fixed-effect model with odds ratios (ORs) and 95% confidence intervals (CIs).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-01-09 11:48:13 +0000" MODIFIED_BY="[Empty name]">
<P>We included two studies in this review, both of which were double-blind, randomised controlled trials comparing perioperative beta-adrenergic blockade (metoprolol) with placebo, on cardiovascular outcomes in people undergoing major non-cardiac vascular surgery. We included 599 participants receiving beta-adrenergic blockers (301 participants) or placebo (298 participants). The overall quality of studies was good. However, one study did not report random sequence generation or allocation concealment techniques, indicating possible selection bias, and the other study did not report outcome assessor blinding and was possibly underpowered. It should be noted that several of the outcomes were only reported in a single study and neither of the studies reported on vascular patency/graft occlusion, which reduces the quality of evidence to moderate. There was no evidence that perioperative beta-adrenergic blockade reduced all-cause mortality (OR 0.62, 95% CI 0.03 to 15.02), cardiovascular mortality (OR 0.34, 95% CI 0.01 to 8.32), non-fatal myocardial infarction (OR 0.83, 95% CI 0.46 to 1.49; P value = 0.53), arrhythmia (OR 0.70, 95% CI 0.26 to 1.88), heart failure (OR 1.71, 95% CI 0.40 to 7.23), stroke (OR 2.67, 95% CI 0.11 to 67.08), composite cardiovascular events (OR 0.87, 95% CI 0.55 to 1.39; P value = 0.57) or re-hospitalisation at 30 days (OR 0.86, 95% CI 0.48 to 1.52). However, there was strong evidence that beta-adrenergic blockers increased the odds of intra-operative bradycardia (OR 4.97, 95% CI 3.22 to 7.65; P value &lt; 0.00001) and intra-operative hypotension (OR 1.84, 95% CI 1.31 to 2.59; P value = 0.0005).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-01-09 11:48:16 +0000" MODIFIED_BY="[Empty name]">
<P>This meta-analysis currently offers no clear evidence that perioperative beta-adrenergic blockade reduces postoperative cardiac morbidity and mortality in people undergoing major non-cardiac vascular surgery. There is evidence that intra-operative bradycardia and hypotension are more likely in people taking perioperative beta-adrenergic blockers, which should be weighed with any benefit.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-01-09 11:48:39 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-01-09 11:48:37 +0000" MODIFIED_BY="[Empty name]">
<P>Non-cardiac, vascular surgery includes a broad range of surgical types. These include, but are not limited to, bypass, angioplasty and stenting, aortic aneurysm repair, amputation, reconstruction of deep vein occlusion, dialysis access and treatment for thoracic outlet syndrome. Vascular surgery is associated with a high risk of perioperative and postoperative morbidity and mortality due to cardiovascular complications, largely because many people undergoing vascular surgery are at risk of coronary artery disease (<LINK REF="REF-ESC_x002f_ESA-2014" TYPE="REFERENCE">ESC/ESA 2014</LINK>). After aortic aneurysm repair, cardiac complications occur in 2.8% of people treated endovascularly and as high as 7.8% of people treated by open repair (<LINK REF="REF-Nowygrod-2006" TYPE="REFERENCE">Nowygrod 2006</LINK>). Two studies found that perioperative myocardial infarction could range from 5% to as high as 24% (<LINK REF="REF-Landesberg-2003" TYPE="REFERENCE">Landesberg 2003</LINK>; <LINK REF="REF-Le-Manach-2005" TYPE="REFERENCE">Le Manach 2005</LINK>). People with severe symptoms of peripheral arterial disease often require vascular surgery to manage their progressing disease. Using modelling methods, it is estimated that within European Union member states there are annually at least 167,000 cardiac complications due to non-cardiac surgeries, with 19,000 being life-threatening (<LINK REF="REF-ESC_x002f_ESA-2014" TYPE="REFERENCE">ESC/ESA 2014</LINK>). These numbers are expected to increase as the population ages and the number of cardiovascular risk factors also increases within this population. To try to manage this increase in cardiac risk the American College of Cardiology/American Heart Association has developed a task force to address risk evaluation of people receiving non-cardiac surgery, in an attempt to reduce cardiac complications (<LINK REF="REF-Fleisher-2007" TYPE="REFERENCE">Fleisher 2007</LINK>), and the European Society of Cardiology and European Society of Anaesthesiology have put out joint guidelines for healthcare workers to offer best management strategies for this patient population (<LINK REF="REF-ESC_x002f_ESA-2014" TYPE="REFERENCE">ESC/ESA 2014</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-01-09 11:48:38 +0000" MODIFIED_BY="[Empty name]">
<P>Beta-adrenergic receptor blockers (beta-blockers) are a class of medications taken orally or intravenously, that are used in the treatment of many forms of heart conditions, as well as suggested for migraines and muscle tremors. Beta-adrenergic blockers have the ability to bind to adrenergic receptors meant for the catecholamines noradrenaline (norepinephrine) and adrenaline (epinephrine), which would normally act to increase the body's ability to withstand stress, by increasing the heart rate, heart muscle contraction, and blood pressure, and allowing more oxygen to reach the lungs (<LINK REF="REF-Frishman-2003" TYPE="REFERENCE">Frishman 2003</LINK>). However, when a beta-adrenergic blocker binds to the adrenergic receptor, the catecholamines cannot bind and there is a general slowing of the heart rate and reduced blood pressure. Adrenergic receptors are found in the heart, blood vessels, lungs and brain, and the various types of beta-adrenergic blockers on the market will act comparatively on the heart, but with varying effects on the blood vessels and lungs (<LINK REF="REF-Frishman-2003" TYPE="REFERENCE">Frishman 2003</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-01-09 11:48:38 +0000" MODIFIED_BY="[Empty name]">
<P>Drugs that block beta-adrenergic receptors have been established as a therapeutic intervention in prevention of cardiac complications in people with acute myocardial infarction, silent cardiac ischaemia, and heart failure. It has been proposed that beta-adrenergic blockers reduce the risk of perioperative cardiac complications by slowing heart rate, decreasing blood pressure, and moderating haemodynamic stress responses (<LINK REF="REF-Frishman-2003" TYPE="REFERENCE">Frishman 2003</LINK>). Doing this reduces the amount of oxygen consumed by the heart, which results in longer diastolic filling and decreased myocardial contractility (<LINK REF="REF-ESC_x002f_ESA-2014" TYPE="REFERENCE">ESC/ESA 2014</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-01-09 11:48:39 +0000" MODIFIED_BY="[Empty name]">
<P>With an increase in the ageing population, the need for vascular surgery will increase, as will the risk of cardiac complications, as coronary artery disease is also on the rise. Treatments to reduce cardiac risk during vascular surgery are needed in order to treat people effectively and safely. One trial published in 1996, which evaluated perioperative beta-adrenergic blockade in people considered at high risk of coronary artery disease and undergoing major surgical procedures, found reduced all-cause mortality in the participants who received beta-adrenergic blockade. This reduction was primarily due to a decrease in cardiovascular mortality in the group receiving beta-adrenergic blockade in the first six to eight months after surgery (<LINK REF="STD-Mangano-1996" TYPE="STUDY">Mangano 1996</LINK>). A more recent study also showed a decrease in composite 30-day death, myocardial infarction and non-fatal cardiac arrest, but the large decrease in non-fatal myocardial infarction was offset by an increase in deaths in the beta-adrenergic blocker group (<LINK REF="STD-POISE-Trial-2006" TYPE="STUDY">POISE Trial 2006</LINK>). Another study showed similar incidence of combined death, myocardial infarction, unstable angina, and heart failure at 30 days between the treatment groups, although it should be kept in mind that the risk factor profile of this trial was different (<LINK REF="STD-Juul-2006" TYPE="STUDY">Juul 2006</LINK>). These studies included participants undergoing all types of major surgery, and not specifically vascular surgery. It cannot currently be determined what results would be seen in people undergoing vascular surgery alone.</P>
<P>A large body of evidence evaluating perioperative beta-adrenergic blockade in people undergoing vascular surgery came from a line of studies known as <LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK> (Dutch Echo-cardiographic Cardiac Risk Evaluation Applying Stress Echocardiography). The primary investigator of the studies, Don Poldermans, has been removed from his position as the head of perioperative cardiac care at Erasmus Medical Centre in Rotterdam, due to scientific misconduct. After investigation, several of the <LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK> studies have been found to have untrustworthy findings due to breaches in protocol, and possible falsifications of data. The lack of integrity of the findings of these studies, which predominantly found beta-adrenergic blockers to have positive effects on morbidity and mortality, has made understanding the role beta-adrenergic blockers play in people undergoing vascular surgery confusing for both clinicians and researchers. <LINK REF="REF-Priebe-2014" TYPE="REFERENCE">Priebe 2014</LINK> highlighted this confusion in a commentary. Guidelines established by the American College of Cardiology Foundation/American Heart Association and the European Society of Cardiology are currently being re-drafted in light of the concerns with the <LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK> trials as well as other recent findings (<LINK REF="REF-ESC-2013" TYPE="REFERENCE">ESC 2013</LINK>; <LINK REF="REF-ESC-2014" TYPE="REFERENCE">ESC 2014</LINK>). Erasmus Medical Center published a full copy of the report regarding the <LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK> studies (<LINK REF="REF-Erasmus-MC-2012" TYPE="REFERENCE">Erasmus MC 2012</LINK> <A HREF="http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en">http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en</A>). In consideration of these uncertainties, we plan to review the current literature and assess the overall efficacy and safety of perioperative beta-adrenergic blockers in reducing cardiovascular morbidity and mortality in people undergoing major non-cardiac vascular surgery.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-01-09 11:48:39 +0000" MODIFIED_BY="[Empty name]">
<P>To review the efficacy and safety of perioperative beta-adrenergic blockade in reducing cardiac or all-cause mortality, myocardial infarction, and other cardiovascular safety outcomes in people undergoing major non-cardiac vascular surgery.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-01-09 11:48:42 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-01-09 11:48:40 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-01-09 11:48:39 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised controlled trials of perioperative beta-adrenergic blockade.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-01-09 11:48:39 +0000" MODIFIED_BY="[Empty name]">
<P>Adults over 18 years of age undergoing non-cardiac vascular surgery.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-01-09 11:48:39 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Intervention: perioperative beta-adrenergic blockers of any dose, titration, duration and mode of administration.</LI>
<LI>Control: placebo or no treatment.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-01-09 11:48:40 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-01-09 11:48:39 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>All-cause mortality.</LI>
<LI>Cardiovascular mortality.</LI>
<LI>30-day postoperative non-fatal and fatal myocardial infarction.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-01-09 11:48:40 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Arrhythmia (any variation from the normal rhythm of the heart beat) requiring treatment.</LI>
<LI>Heart failure.</LI>
<LI>Vascular patency/graft occlusion.</LI>
<LI>Stroke.</LI>
<LI>Composite 30-day cardiovascular outcomes.</LI>
<LI>Intra-operative bradycardia.</LI>
<LI>Intra-operative hypotension.</LI>
<LI>Re-hospitalisation at 30 days.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-01-09 11:48:40 +0000" MODIFIED_BY="[Empty name]">
<P>We applied no language restrictions.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-01-09 11:48:40 +0000" MODIFIED_BY="[Empty name]">
<P>The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched January 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 12, part of <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Peripheral Vascular Diseases Group module in <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>).</P>
<P>The TSC searched the following trial databases for details of ongoing and unpublished studies using the terms vascular surgery and beta:</P>
<UL>
<LI>World Health Organization (WHO) International Clinical Trials Registry (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch/</A>);</LI>
<LI>ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">clinicaltrials.gov/</A>);</LI>
<LI>ISRCTN register (<A HREF="http://www.controlled-trials.com/isrctn/">/www.controlled-trials.com/isrctn/</A>).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-01-09 11:48:40 +0000" MODIFIED_BY="[Empty name]">
<P>We reviewed the reference lists of all included studies for further relevant studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-01-09 11:48:42 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-01-09 11:48:40 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (KM and RB) independently used selection criteria to assess titles and abstracts of all studies identified in the search. We reviewed full references where necessary. We included studies meeting the inclusion criteria and documented reasons for exclusion of any article. We addressed disagreement of study selection through discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-01-09 11:48:41 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (KM and RB) independently processed articles that met the inclusion criteria for data extraction. We checked results for consistency using a prepared data extraction form. We extracted the following details from the included studies: number of participants in each arm, participant characteristics (age, gender, and cardiovascular risk factors), type of vascular surgery, specific beta-adrenergic blocker used (including dose and duration), study outcomes, adverse effects reported, and length of trial follow-up. We resolved any disagreements through discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-01-09 11:48:41 +0000" MODIFIED_BY="[Empty name]">
<P>Risk of bias was assessed by RB and MS according to The Cochrane Collaboration 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This tool consists of six domains of bias: selection bias, performance bias, detection bias, attrition bias, reporting bias and other potential sources of bias. We allocated scores of high risk and low risk of bias according to the guidelines described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If insufficient information was available to allocate high or low risk, we deemed the study to be of unclear risk of bias. We resolved any disagreements through discussion.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-01-09 11:48:41 +0000" MODIFIED_BY="[Empty name]">
<P>As all primary and secondary outcomes are dichotomous, we expressed data as odds ratio (ORs) with 95% confidence intervals (CIs) using a fixed-effect model. However, if the test for heterogeneity yielded an I<SUP>2</SUP> statistic greater than 50%, we used a random-effects model.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-01-09 11:48:41 +0000" MODIFIED_BY="[Empty name]">
<P>Due to the nature of the condition and intervention, we considered only randomised participants for inclusion in analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-01-09 11:48:41 +0000" MODIFIED_BY="[Empty name]">
<P>We based quantitative analysis of outcomes on an intention-to-treat basis, using all participants randomised. If data on drop-outs, withdrawals or other missing data were not reported, we attempted to contact study authors.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-01-09 11:48:41 +0000" MODIFIED_BY="[Empty name]">
<P>A test for heterogeneity examines the null hypothesis that all studies are evaluating the same effect. We obtained P values comparing the test statistic with a Chi<SUP>2</SUP> distribution. To help readers assess the consistency of results of studies in a meta-analysis Review Manager 5 software includes a method (I<SUP>2 </SUP>statistic) that describes the percentage of total variation across studies due to heterogeneity above what is expected by chance (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We analysed data with more than 50% heterogeneity using a random-effects model to account for issues of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-01-09 11:48:41 +0000" MODIFIED_BY="[Empty name]">
<P>To assess reporting bias, we planned to construct funnel plots for meta-analyses with sufficient number of trials included (more than 10) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). As only two studies were included, we did not evaluate reporting bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-01-09 11:48:41 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to perform meta-analyses for each primary and secondary outcome using fixed-effect models. However, if the test for heterogeneity yielded an I<SUP>2</SUP> statistic greater than 50%, we used a random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-01-09 11:48:42 +0000" MODIFIED_BY="[Empty name]">
<P>Where possible, we planned to analyse subgroups based on type of surgery, vascular risk of study population, duration of drug therapy, and intensity of drug therapy. However, neither of the two included studies provided outcome data based on these characteristics, therefore, we could not perform subgroup analysis.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-01-09 11:48:42 +0000" MODIFIED_BY="[Empty name]">
<P>If sufficient trials were available, we planned to conduct sensitivity analysis by excluding studies at high risk of bias. However, as we included only two studies, both of good quality, in the analysis, we could not perform sensitivity analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-01-09 11:48:45 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-01-09 11:48:43 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-01-09 11:48:42 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. Two studies (four records) met the review inclusion criteria (<LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK>; <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK>). We excluded 24 references from nine studies (<LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK>; <LINK REF="STD-Duranay-2010" TYPE="STUDY">Duranay 2010</LINK>; <LINK REF="STD-Juul-2006" TYPE="STUDY">Juul 2006</LINK>; <LINK REF="STD-Mangano-1996" TYPE="STUDY">Mangano 1996</LINK>; <LINK REF="STD-POISE-Trial-2006" TYPE="STUDY">POISE Trial 2006</LINK>; <LINK REF="STD-Ralley-1988" TYPE="STUDY">Ralley 1988</LINK>; <LINK REF="STD-Stone-1988" TYPE="STUDY">Stone 1988</LINK>; <LINK REF="STD-Suttner-2009" TYPE="STUDY">Suttner 2009</LINK>; <LINK REF="STD-Zaugg-1999" TYPE="STUDY">Zaugg 1999</LINK>).<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-01-09 11:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for more details.</P>
<P>We identified two double-blind, randomised controlled trials that fulfilled our eligibility criteria (<LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK>; <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK>). A total of 599 participants were randomised to receive either perioperative beta-adrenergic blockade or placebo; the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study included 496 participants while the <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study included 103. The <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study excluded participants with the highest cardiovascular risk, such as people who had had a previous myocardial infarction. The <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study had more lenient criteria. The type of non-cardiac vascular surgery varied between the two trials and included aortic aneurysm repair, aorto-iliac grafts for stenosis, femo-femoral cross-over grafts, femoro-popliteal bypass, femoro-distal bypass, amputation, infrainguinal re-vascularisation and axillofemoral re-vascularisation.</P>
<P>The <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study followed a protocol with the beta-adrenergic blocker metoprolol, using a weight-based dosage: participants weighing 75 kg or greater received a dosage of 100 mg, participants weighing between 40 and 70 kg received 50 mg, and participants weighing 40 kg or less received 25 mg. The study medication was given orally (twice daily) or intravenously (every six hours) beginning two hours pre-operatively until hospital discharge, or a maximum of five days postoperatively. The <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study followed a different protocol, also with metoprolol, which was given in 2 to 4 mg intravenous injections beginning five to 10 minutes before intubation, followed by 50 mg twice daily (orally) for seven days after surgery. All participants in the <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study underwent a test dosage of metoprolol prior to surgery to make sure the drug was well tolerated. Both studies were double-blinded, and, therefore, used a placebo regimen that matched that of metoprolol.</P>
<P>The reported outcomes in the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study were non-fatal myocardial infarction, unstable angina, new congestive heart failure, new atrial or ventricular dysrhythmia requiring treatment, or cardiac death. The <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study identified outcomes of interest as fatal and non-fatal cardiovascular events within 30 days of surgery, myocardial ischaemia per 24 hours, length of postoperative hospital stay, and two-year survival. Both studies included a composite 30-day cardiovascular event outcome with the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study combining cardiac death, non-fatal myocardial infarction, congestive heart failure, unstable angina, and dysrhythmia requiring treatment, and the <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study combining fatal and non-fatal myocardial infarction, unstable angina, stroke, and ventricular tachycardia.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-01-09 11:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for more details.</P>
<P>We excluded nine studies (<LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK>; <LINK REF="STD-Duranay-2010" TYPE="STUDY">Duranay 2010</LINK>; <LINK REF="STD-Juul-2006" TYPE="STUDY">Juul 2006</LINK>; <LINK REF="STD-Mangano-1996" TYPE="STUDY">Mangano 1996</LINK>; <LINK REF="STD-POISE-Trial-2006" TYPE="STUDY">POISE Trial 2006</LINK>; <LINK REF="STD-Ralley-1988" TYPE="STUDY">Ralley 1988</LINK>; <LINK REF="STD-Stone-1988" TYPE="STUDY">Stone 1988</LINK>; <LINK REF="STD-Suttner-2009" TYPE="STUDY">Suttner 2009</LINK>; <LINK REF="STD-Zaugg-1999" TYPE="STUDY">Zaugg 1999</LINK>). We excluded the <LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK> studies due to concerns with integrity of the data and collection method. The Erasmus Medical Center produced a full report on the <LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK> studies (<LINK REF="REF-Erasmus-MC-2012" TYPE="REFERENCE">Erasmus MC 2012</LINK>) and can be found at this link: <A HREF="http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en">http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en</A>. We excluded five studies because the outcomes are not currently within the scope of this review (<LINK REF="STD-Duranay-2010" TYPE="STUDY">Duranay 2010</LINK>; <LINK REF="STD-Ralley-1988" TYPE="STUDY">Ralley 1988</LINK>; <LINK REF="STD-Stone-1988" TYPE="STUDY">Stone 1988</LINK>; <LINK REF="STD-Suttner-2009" TYPE="STUDY">Suttner 2009</LINK>; <LINK REF="STD-Zaugg-1999" TYPE="STUDY">Zaugg 1999</LINK>). We excluded three studies because their study population included people undergoing other types of surgery, not just vascular, and subgroup data for people undergoing vascular surgery could not be extracted separately (<LINK REF="STD-Juul-2006" TYPE="STUDY">Juul 2006</LINK>; <LINK REF="STD-Mangano-1996" TYPE="STUDY">Mangano 1996</LINK>; <LINK REF="STD-POISE-Trial-2006" TYPE="STUDY">POISE Trial 2006</LINK>). We contacted the authors of these three studies for outcome data specific to people undergoing vascular surgery.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-01-09 11:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2015-01-09 11:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation bias for the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study was unclear, as the randomisation sequence generation method was not fully clarified and allocation concealment was not addressed. The <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study was at low risk of allocation bias as both randomisation sequence generation and allocation concealment were managed through a dedicated central website.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-01-09 11:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>Blinding of participants and personnel was adequate in both studies, with the use of identical placebos. In the <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study, the anaesthesiologists were not blinded to the study drug, for safety reasons, but precautions were taken to ensure only the anaesthesiologists knew of the study medication, and no other carer or investigator. Blinding of assessors was adequate in the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study, as a blinded adjudication committee was utilised;this was not adequately discussed in the <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study, putting it an unclear risk of detection bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-01-09 11:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>Attrition bias was low for both studies because they adequately reported participant drop-out rates and reasons, with similar rates occurring between groups in both studies.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-01-09 11:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>Both the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> and <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> studies had low risk of reporting bias because all pre-specified outcomes were reported on.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-01-06 12:12:41 +0000" MODIFIED_BY="Anne Lawson">
<P>The <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study did not appear to have any other sources of bias, but the <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study had unclear risk of other bias, as their power calculation determined a need of 300 participants in their study population, but they only recruited 103, leaving the study possibly underpowered.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-01-09 11:48:45 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Beta-adrenergic blocker versus placebo or no treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">All-cause mortality</HEADING>
<P>Both the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> and <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> studies reported all-cause mortality for the comparison of beta-adrenergic blockers and placebo. Due to heterogeneity, we used a random-effects model (see <LINK TAG="DATA_SYNTHESIS" TYPE="SECTION">Data synthesis</LINK>), which found no clear difference between the two interventions (OR 0.62, 95% CI 0.03 to 15.02; P value = 0.77; I<SUP>2</SUP> = 66%; n = 599). However, the CI is very wide, making any conclusion for the association difficult to make.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cardiovascular mortality</HEADING>
<P>Cardiovascular mortality was only evaluated in the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study, and there was a single event in the placebo group, so there was no clear evidence that beta-adrenergic blockers reduced cardiovascular mortality (OR 0.34, 95% CI 0.01 to 8.32; n = 496). No overall association could be determined from the model as only one study was included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Non-fatal myocardial infarction</HEADING>
<P>Both the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> and <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> studies evaluated non-fatal myocardial infarction, and the fixed-effect model found no difference between the two treatment groups(OR 0.83, 95% 0.46 to 1.49; P value = 0.53; n = 599).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Arrhythmia</HEADING>
<P>Only the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> recorded arrhythmia, so no overall association could be determined. There was no clear evidence that perioperative beta-adrenergic blockers reduced arrhythmia (OR 0.70, 95% CI 0.26 to 1.88; n = 496).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Heart failure</HEADING>
<P>Only the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> recorded heart failure, and there was no clear evidence to support beta-adrenergic blockers reducing heart failure (OR 1.71, 95% CI 0.40 to 7.23; n = 496).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vascular patency/graft occlusion</HEADING>
<P>Neither of the included studies evaluated vascular patency/graft occlusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stroke</HEADING>
<P>The <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study evaluated stroke, which found an OR of 2.67 (95% CI 0.11 to 67.08; n = 103), but only one event was recorded (in the beta-adrenergic blocker group) so the CI is very wide and uninformative. No overall association could be derived from the single study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Composite 30-day cardiovascular outcomes</HEADING>
<P>Th <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> and <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> studies evaluated a composite of cardiovascular outcomes at 30 days. There was no statistically significant difference between beta-adrenergic blockers and placebo (OR of 0.87, 95% CI 0.55 to 1.39; P value = 0.57; n = 599). It should be noted that although both studies were using a similar definition for a composite cardiovascular outcome, the two studies had slight differences in which events made up this outcome; this should be kept in mind when interpreting the findings.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intra-operative bradycardia</HEADING>
<P>
<LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> and <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> evaluated intra-operative bradycardia, and the fixed-effect model found a strong, statistically significant increase in the odds of intra-operative bradycardia in the beta-adrenergic blocker group compared with placebo(OR 4.97, 95% CI 3.22 to 7.65; P value &lt; 0.00001; n = 599).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intra-operative hypotension</HEADING>
<P>
<LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> and <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> measured episodes of intra-operative hypotension. The fixed-effect model found a statistically significant increase in the odds of experiencing hypotension in the beta-adrenergic blocker group compared with placebo (OR 1.84, 95% CI 1.31 to 2.59; P value = 0.0005; n = 599).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Re-hospitalisation at 30 days</HEADING>
<P>Only the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study evaluated re-hospitalisation at 30 days, and found no clear evidence supporting reduced re-hospitalisation in the beta-adrenergic blocker group (OR 0.86, 95% CI 0.48 to 1.52; n = 496).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-01-09 11:48:45 +0000" MODIFIED_BY="[Empty name]">
<P>We identified only two studies that met the eligibility criteria for inclusion in the review (<LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK>; <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK>). Both studies were double-blind, randomised controlled trials comparing perioperative beta-adrenergic blockade (metoprolol) with placebo on cardiovascular outcomes in people undergoing non-cardiac vascular surgery. Combined, there were 599 participants included in this review; 301 received beta-adrenergic blockers and 298 received placebo. The results give no clear evidence that perioperative beta-adrenergic blockade reduces all-cause mortality, cardiovascular mortality, or cardiovascular events. There was strong evidence that perioperative beta-adrenergic blockers increase the odds of intra-operative bradycardia and hypotension. For many of the outcomes, there were very few data points with data for some outcomes from only one study. This resulted in wide CIs for several outcomes, and unclear interpretation of the results. We conclude that, based on the current level of evidence, there is insufficient data to understand fully the effects of routine perioperative beta-adrenergic blockade in people undergoing major non-cardiac vascular surgery.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-01-09 11:48:46 +0000" MODIFIED_BY="[Empty name]">
<P>The two studies included in this review offered relevant evidence to the review question. However, with only two studies, there was not enough data to address the objectives of the review sufficiently. The addition of relevant data was limited by study design, as several other studies addressing the same study question, but in a heterogeneous population of people undergoing major surgery, did not make outcome data available specific to people undergoing vascular surgery. There were differences between the two studies, with the <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study population selected to have a lower cardiovascular risk, which was not done in the <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study. In addition, the composite cardiovascular events reported in the two studies were compiled of slightly different events. This review did not evaluate dosage or pre-treatment of beta-adrenergic blockers, and neither of the included studies titrated the beta-adrenergic blocker to a target heart rate. In addition, as both included studies evaluated metoprolol, the current evidence is only specific to this medication.</P>
<P>Guidelines established in 2009 from the American College of Cardiology Foundation and American Heart Association (ACCF/AHA) recommend beta-adrenergic blockers for people undergoing vascular surgery who are at a higher cardiac risk, but are uncertain to recommend beta-adrenergic blockers in people undergoing vascular surgery with low or no cardiac risk (<LINK REF="REF-ACCF_x002f_AHA-2009" TYPE="REFERENCE">ACCF/AHA 2009</LINK>). However, due to the uncertainty that has occurred after the controversies with the <LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK> trials became apparent (<LINK REF="REF-Erasmus-MC-2012" TYPE="REFERENCE">Erasmus MC 2012</LINK> : <A HREF="http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en">http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en</A>), as well as other recent findings, the ACCF/AHA and the European Society of Cardiology (ESC) have published a joint statement that new guidelines are being constructed. In the interim, the recommendation is "initiation of beta blockers in patients who will undergo non-cardiac surgery should not be considered routine, but should be considered carefully by each patient's treating physician on a case-by-case basis" (<LINK REF="REF-ESC-2013" TYPE="REFERENCE">ESC 2013</LINK>; <LINK REF="REF-ESC-2014" TYPE="REFERENCE">ESC 2014</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-01-09 11:48:46 +0000" MODIFIED_BY="[Empty name]">
<P>The quality of reporting in both studies was good. The <LINK REF="STD-MaVS-2006" TYPE="STUDY">MaVS 2006</LINK> study did not report how their randomisation sequence was generated or how they maintained allocation concealment, but was otherwise at low risk of bias. The quality of the <LINK REF="STD-POBBLE-2005" TYPE="STUDY">POBBLE 2005</LINK> study was only limited by unclear reporting bias, as there were no two-year data reported, as indicated by the study authors, and a possibly underpowered study population. However, with only two studies, totalling 599 randomised participants, differences in outcome reporting, and not all outcomes being reported on, the quality of the evidence was moderate, and not currently robust enough to draw any conclusions on whether perioperative beta-adrenergic blockade reduces cardiovascular risk in people undergoing non-cardiac vascular surgery.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-01-09 11:48:46 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently performed study selection, quality assessment and data extraction in order to reduce any bias. It was the choice of the review authors not to include the <LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK> studies due to the uncertainties of the integrity of the data. In addition, we could not use three excluded studies because they did not publish subgroup analysis of the outcomes of people who underwent vascular surgery. We attempted to contact study authors for this data, but received no response. While every attempt was made to identify any relevant studies, there is the possibility that we overlooked unpublished studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>While there are several reviews that have evaluated cardiovascular outcomes comparing perioperative beta-adrenergic blockade usage with a control in people undergoing major non-cardiac surgery, this is the first review, to our knowledge, evaluating this comparison on people undergoing vascular surgery, using only prospective, randomised controlled trials.</P>
<P>One review conducted in 2010 evaluated perioperative beta-adrenergic blockade in people undergoing vascular surgery, but the authors included retrospective and observational studies, in addition to randomised controlled trials, including the two trials included in our review (<LINK REF="REF-Brooke-2010" TYPE="REFERENCE">Brooke 2010</LINK>). This review also included data from the <LINK REF="STD-DECREASE-2010" TYPE="STUDY">DECREASE 2010</LINK> studies, as it was published before the controversy with its principal investigator. Meta-analysis was not utilised as the outcomes of the included studies varied widely, and, therefore, the results were evaluated through narrative synthesis. The authors concluded that perioperative beta-adrenergic blockade usage lowers the risk of myocardial infarction and cardiovascular death, but that the risk of adverse events, such as bradycardia, is increased. These conclusions were not drawn through quantitative evaluation, and it should be noted that the only two studies that met inclusion criteria for our own review showed no benefit of beta-adrenergic blockers on cardiovascular events, whereas the remaining eight studies showed a benefit of beta-adrenergic blockade, but for differing cardiac outcomes. The authors of the <LINK REF="REF-Brooke-2010" TYPE="REFERENCE">Brooke 2010</LINK> review also used studies evaluating people undergoing major surgery, not specific to vascular surgery, to draw their conclusions, making their findings not actually specific to people undergoing vascular surgery. The findings of our meta-analyses do not currently agree with this review, as we found no clear evidence suggesting reduced cardiovascular risk from the use of perioperative beta-adrenergic blockers in people undergoing vascular surgery.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>It is currently unclear whether perioperative beta-adrenergic blockers reduce cardiac complications in people undergoing non-cardiac vascular surgery. This review indicates that beta-adrenergic blockers increase the risk of intra-operative bradycardia and hypotension, which should be weighed against any possible benefit.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>There is a clear need for additional randomised controlled trials to evaluate the effects of perioperative beta-adrenergic blockade in people undergoing non-cardiac vascular surgery. Future research should aim to investigate pre-treatment, dosage, and duration of beta-adrenergic blockade, as these currently vary between studies. In addition, of great importance would be the evaluation of perioperative beta-adrenergic blockade usage based on cardiovascular risk. There are already several large trials that evaluated the comparison of interest in people undergoing major, non-cardiac surgery, that included vascular surgery, and if the study authors of these trials made the outcome data specific to people undergoing vascular surgery available, this would greatly increase relevant data available for this population.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors would like to thank Marlene Stewart for assistance with risk of bias and the Peripheral Vascular Diseases Review Group for the guidance during the review process.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>KM: none known.<BR/>RB: none known.<BR/>DH: I have received consultancy fees from Jansenn Pharmaceutics, expert testimony fees from Massey and Associates Law Practice, Phoenix, AZ, payment for lectures from Jansenn Pharmaceuticals and American College of Physicians and travel and meeting expenses from BMS/Pfizer Pharmaceuticals and University of Massachusetts. My Institution has received grant funding from BMS/Pfizer Pharmaceuticals, National Institutes of Health and University of Massachusetts. The subject matter represented by my disclosures are limited to the field of venous thromboembolism and anticoagulation. I have no conflicts related to the current review topic.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Katayoun Mostafaie reviewed articles for inclusion, assessed the quality of selected studies, extracted data and wrote the text of the review.</P>
<P>Rachel Bedenis reviewed articles for inclusion, assessed the quality of the selected studies, extracted data and assisted in drafting the review.</P>
<P>Darrell Harrington reviewed articles for inclusion, assessed the quality of selected studies, extracted data and contributed to the text of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>According to updated guidelines from The Cochrane Collaboration, we assessed the methodological quality of the studies using the 'Risk of bias' tool described by <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-01-09 11:53:12 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-01-09 11:53:05 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-01-09 11:50:04 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-MaVS-2006" MODIFIED="2015-01-06 12:12:31 +0000" MODIFIED_BY="Anne Lawson" NAME="MaVS 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-03-03 12:08:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang H, Raymer K, Butler R, Parlow J, Roberts R</AU>
<TI>Metoprolol after vascular surgery</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>Suppl 1</NO>
<PG>A7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 10:26:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yang H. Raymer K. Butler R. Parlow J. Roberts R</AU>
<TI>The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial</TI>
<SO>American Heart Journal</SO>
<YR>2006</YR>
<VL>152</VL>
<NO>5</NO>
<PG>983-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-POBBLE-2005" MODIFIED="2015-01-09 11:50:04 +0000" MODIFIED_BY="[Empty name]" NAME="POBBLE 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-07-01 10:26:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Brady AR. Gibbs JS. Greenhalgh RM. Powell JT. Sydes MR. POBBLE trial investigators. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial.[see comment]. [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Journal of Vascular Surgery. 41(4):602-9, 2005 Apr. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-07-01 10:26:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR. POBBLE trial investigators</AU>
<TI>Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>4</NO>
<PG>602-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-09 11:50:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN13072628</AU>
<TI>A prospective, randomised controlled trial of beta-blockade in intermediate and high risk vascular surgery, 2002</TI>
<SO>www.controlled-trials.com/ISRCTN13072628</SO>
<YR>(accessed 18 July 2014)</YR>
<IDENTIFIERS MODIFIED="2015-01-06 11:46:03 +0000" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-01-09 11:53:05 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-DECREASE-2010" MODIFIED="2015-01-09 11:50:37 +0000" MODIFIED_BY="[Empty name]" NAME="DECREASE 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-01-09 11:50:14 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20110817&lt;/p&gt;" NOTES_MODIFIED="2015-01-09 11:50:14 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bakker EJ, Ravensbergen NJ, Voute MT, Hoeks SE, Chonchol M, Klimek M, et al</AU>
<TI>A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery: rationale and design of DECREASE-XIII</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2011</YR>
<VL>42</VL>
<NO>3</NO>
<PG>317-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-09 11:50:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunklegrun M, Boersma E, Koopman-Van Gemert AW, van Poorten F, Kalkman C, Schouten O, et al</AU>
<TI>Fluvastatin and bisoprolol for cardiac risk reduction in intermediate-risk patients undergoing non-cardiovascular surgery: a randomised controlled trial</TI>
<SO>European Heart Journal</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>Suppl</NO>
<PG>602-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-09 11:50:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunklegrun M, Boersma E, Schouten O, Koopman-Van Gemert AW, van Poorten F, Bax JJ, et al</AU>
<TI>Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing non-cardiovascular surgery: a randomized controlled trial (DECREASE-IV)</TI>
<SO>Annals of Surgery</SO>
<YR>2009</YR>
<VL>249</VL>
<NO>6</NO>
<PG>921-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 10:33:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lier F, Schouten O, Hoeks SE, Ven L, Stolker RJ, Bax JJ, et al</AU>
<TI>Impact of prophylactic beta-blocker therapy to prevent stroke after noncardiac surgery</TI>
<SO>American Journal of Cardiology</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>1</NO>
<PG>43-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-31 12:42:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poldermans D, Boersma E, Bax JJ, Thomson IR, Paelinck B, Van de Ven LLM, et al</AU>
<TI>Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery</TI>
<SO>European Heart Journal</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>15</NO>
<PG>1353-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-31 12:44:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Poldermans D. Boersma E. Bax JJ. Thomson IR. van de Ven LL. Blankensteijn JD. Baars HF. Yo TI. Trocino G. Vigna C. Roelandt JR. van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] New England Journal of Medicine. 341(24):1789-94, 1999 Dec 9.&lt;/p&gt;" NOTES_MODIFIED="2014-01-31 12:44:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, et al</AU>
<TI>The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>24</NO>
<PG>1789-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-05 16:42:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schouten O, Poldermans D, Visser L, Kertai MD, Klein J, van Urk H, et al</AU>
<TI>Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study</TI>
<SO>American Heart Journal</SO>
<YR>2004</YR>
<VL>148</VL>
<NO>6</NO>
<PG>1047-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duranay-2010" MODIFIED="2015-01-06 11:49:15 +0000" MODIFIED_BY="Anne Lawson" NAME="Duranay 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-01-06 11:49:15 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duranay M, Kanbay M, Akay H, Unverdi S, Surer H, Altay M, et al</AU>
<TI>Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot study</TI>
<SO>Nephron. Clinical Practice</SO>
<YR>2010</YR>
<VL>114</VL>
<NO>3</NO>
<PG>c213-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juul-2006" MODIFIED="2015-01-09 11:50:44 +0000" MODIFIED_BY="[Empty name]" NAME="Juul 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-01-09 11:50:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Juul AB. Wetterslev J. Gluud C. Kofoed-Enevoldsen A. Jensen G. Callesen T. Norgaard P. Fruergaard K. Bestle M. Vedelsdal R. Miran A. Jacobsen J. Roed J. Mortensen MB. Jorgensen L. Jorgensen J. Rovsing ML. Petersen PL. Pott F. Haas M. Albret R. Nielsen LL. Johansson G. Stjernholm P. Molgaard Y. Foss NB. Elkjaer J. Dehlie B. Boysen K. Zaric D. Munksgaard A. Madsen JB. Oberg B. Khanykin B. Blemmer T. Yndgaard S. Perko G. Wang LP. Winkel P. Hilden J. Jensen P. Salas N. DIPOM Trial Group. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] BMJ. 332(7556):1482, 2006 Jun 24. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-01-09 11:50:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, et al</AU>
<TI>Effect of perioperative beta-blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<NO>7556</NO>
<PG>1482-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-31 12:38:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15077084&lt;br&gt;Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2014-01-31 12:38:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juul AB, Wetterslev J, Kofoed-Enevoldsen A, Callesen T, Jensen G, Gluud C, et al</AU>
<TI>The Diabetic Postoperative Mortality and Morbidity (DIPOM) trial: rationale and design of a multicenter, randomized, placebo-controlled, clinical trial of metoprolol for patients with diabetes mellitus who are undergoing major noncardiac surgery</TI>
<SO>American Heart Journal</SO>
<YR>2004</YR>
<VL>147</VL>
<NO>4</NO>
<PG>677-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mangano-1996" MODIFIED="2014-01-29 11:59:51 +0000" MODIFIED_BY="[Empty name]" NAME="Mangano 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-01-29 11:59:51 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mangano DT. Layug EL. Wallace A. Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group.[see comment][erratum appears in N Engl J Med 1997 Apr 3;336(14):1039]. [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] New England Journal of Medicine. 335(23):1713-20, 1996 Dec 5. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-01-29 11:59:51 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mangano DT, Layug EL, Wallace A, Tateo I</AU>
<TI>Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<NO>23</NO>
<PG>1713-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-POISE-Trial-2006" MODIFIED="2015-01-09 11:51:17 +0000" MODIFIED_BY="[Empty name]" NAME="POISE Trial 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-07-01 10:32:04 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20110419&lt;/p&gt;" NOTES_MODIFIED="2014-07-01 10:32:04 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, et al</AU>
<TI>Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2011</YR>
<VL>154</VL>
<PG>523-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-09 11:50:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Devereaux PJ</AU>
<TI>ACCEL: The Perioperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery</TI>
<SO>ACC Cardiosource Review Journal</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>5</NO>
<PG>30-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-09 11:50:56 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This study has been terminated&lt;/p&gt;" NOTES_MODIFIED="2015-01-09 11:50:56 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Devereaux PJ</AU>
<TI>The PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery</TI>
<SO>Clinical Research in Cardiology</SO>
<YR>2008</YR>
<VL>97</VL>
<NO>1</NO>
<PG>8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 10:31:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leslie K, Myles P, Devereaux P, Williamson E, Rao-Melancini P, Forbes A, et al</AU>
<TI>Neuraxial block, death and serious cardiovascular morbidity in the POISE trial</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2014</YR>
<VL>111</VL>
<NO>3</NO>
<PG>382-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 10:31:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leslie K, Myles P, Devereaux PJ, Forbes A, Rao-Melancini P, Williamson E, et al</AU>
<TI>Nitrous oxide and serious morbidity and mortality in the POISE trial</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2013</YR>
<VL>116</VL>
<NO>5</NO>
<PG>1034-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-09 11:51:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00182039</AU>
<TI>POISE Trial: PeriOperative Ischemic Evaluation Study, 2005</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00182039</SO>
<YR>(accessed 27 June 2014)</YR>
<IDENTIFIERS MODIFIED="2015-01-06 11:52:14 +0000" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-31 10:55:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16875901&lt;br&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2014-01-31 10:55:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>POISE Trial Investigators, Devereaux PJ, Yang H, Guyatt GH, Leslie K, Villar JC, et al</AU>
<TI>Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery</TI>
<SO>American Heart Journal</SO>
<YR>2006</YR>
<VL>152</VL>
<NO>2</NO>
<PG>223-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-31 10:55:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20080515&lt;/p&gt;" NOTES_MODIFIED="2014-01-31 10:55:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>POISE study group</AU>
<TI>Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9627</NO>
<PG>1839-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ralley-1988" MODIFIED="2015-01-09 11:51:24 +0000" MODIFIED_BY="[Empty name]" NAME="Ralley 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-01-09 11:51:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ralley FE, Ramsay JR, Wynands JE, O'Connor JP, Bilodeau J</AU>
<TI>The efficacy of esmolol in the treatment of hypertension after aortic reconstructive surgery</TI>
<SO>Canadian Journal of Anesthesia</SO>
<YR>1988</YR>
<VL>35</VL>
<NO>1 Suppl</NO>
<PG>S73-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stone-1988" MODIFIED="2015-01-09 11:53:05 +0000" MODIFIED_BY="[Empty name]" NAME="Stone 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-01-09 11:53:05 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Stone JG. Foex P. Sear JW. Johnson LL. Khambatta HJ. Triner L. Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] Anesthesiology. 68(4):495-500, 1988 Apr&lt;/p&gt;" NOTES_MODIFIED="2015-01-09 11:53:05 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stone JG, Foex P, Sear JW, Johnson LL, Khambatta HJ, Triner L</AU>
<TI>Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent</TI>
<SO>Anesthesiology</SO>
<YR>1988</YR>
<VL>68</VL>
<NO>4</NO>
<PG>495-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suttner-2009" MODIFIED="2015-01-09 11:51:49 +0000" MODIFIED_BY="[Empty name]" NAME="Suttner 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-01-09 11:51:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00348101</AU>
<TI>Effects of beta-blocker therapy and phosphodiesterase inhibition on cardiac neurohormonal activation, 2007</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00348101</SO>
<YR>(accessed 18 July 2014)</YR>
<IDENTIFIERS MODIFIED="2015-01-06 11:54:45 +0000" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 10:26:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2009371308 200940&lt;/p&gt;" NOTES_MODIFIED="2014-07-01 10:26:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Suttner S, Boldt J, Mengistu A, Lang K, Mayer J</AU>
<TI>Influence of continuous perioperative beta-blockade in combination with phosphodiesterase inhibition on haemodynamics and myocardial ischaemia in high-risk vascular surgery patients</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2009</YR>
<VL>102</VL>
<NO>5</NO>
<PG>597-607</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zaugg-1999" MODIFIED="2014-02-05 12:31:12 +0000" MODIFIED_BY="[Empty name]" NAME="Zaugg 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-02-05 12:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zaugg M, Tagliente T, Lucchinetti E, Jacobs E, Krol M, Boian C, et al</AU>
<TI>Beneficial effects from beta-adrenergic blockade in elderly patients undergoing noncardiac surgery</TI>
<SO>Anesthesiology</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>6</NO>
<PG>1674-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-12-05 07:59:53 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-01-09 11:53:12 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-01-09 11:53:12 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACCF_x002f_AHA-2009" MODIFIED="2015-01-09 11:52:27 +0000" MODIFIED_BY="[Empty name]" NAME="ACCF/AHA 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fleischman KE, Beckman JA, Buller CE, Calkins H, Fleisher LA, Freeman WK, et al</AU>
<TI>2009 ACCF/AHA focused update on perioperative beta blockade: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>120</VL>
<PG>2123-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brooke-2010" MODIFIED="2015-01-09 11:53:12 +0000" MODIFIED_BY="[Empty name]" NAME="Brooke 2010" TYPE="JOURNAL_ARTICLE">
<AU>Brooke BS</AU>
<TI>Perioperative beta-blockers for vascular surgery patients</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2010</YR>
<VL>51</VL>
<PG>515-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erasmus-MC-2012" MODIFIED="2015-01-09 11:52:08 +0000" MODIFIED_BY="[Empty name]" NAME="Erasmus MC 2012" TYPE="OTHER">
<AU>Erasmus MC Follow-up Investigation Committee</AU>
<TI>Report on the 2012 follow-up investigation of possible breaches of academic integrity, 2012. www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en</TI>
<SO>(accessed 5 January 2015)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESC-2013" MODIFIED="2015-01-09 11:52:21 +0000" MODIFIED_BY="[Empty name]" NAME="ESC 2013" TYPE="OTHER">
<AU>ESC Press Office</AU>
<TI>Joint statement: issued by the American College of Cardiology, American Heart Association and the European Society of Cardiology, 2013</TI>
<SO>www.escardio.org/about/press/press-releases/pr-13/Pages/joint-statement-perioperative-guidelines.aspx</SO>
<YR>(accessed 5 January 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESC-2014" MODIFIED="2015-01-09 11:52:44 +0000" MODIFIED_BY="[Empty name]" NAME="ESC 2014" TYPE="OTHER">
<AU>ESC Press Office</AU>
<TI>Beta-blockers and perioperative care: European Heart Journal editorial addresses controversy, 2014</TI>
<SO>www.escardio.org/about/press/press-releases/pr-14/Pages/Beta-Blockers-Perioperative-Care-EHJ-Editorial-addresses-controversy.aspx?hit=dontmiss</SO>
<YR>(accessed 5 January 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESC_x002f_ESA-2014" MODIFIED="2014-11-24 08:45:20 +0000" MODIFIED_BY="[Empty name]" NAME="ESC/ESA 2014" TYPE="JOURNAL_ARTICLE">
<AU>The Joint Task Force on non-cardiac surgery</AU>
<TI>2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management</TI>
<SO>European Heart Journal</SO>
<YR>2014</YR>
<VL>35</VL>
<PG>2383-431</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleisher-2007" MODIFIED="2014-07-06 15:50:12 +0100" MODIFIED_BY="[Empty name]" NAME="Fleisher 2007" TYPE="JOURNAL_ARTICLE">
<AU>Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, et al</AU>
<TI>ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2007</YR>
<VL>50</VL>
<NO>17</NO>
<PG>e159-242</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frishman-2003" MODIFIED="2014-07-06 15:50:23 +0100" MODIFIED_BY="[Empty name]" NAME="Frishman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Frishman WH</AU>
<TI>Beta-adrenergic blockade</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>107</VL>
<PG>e117-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2014-02-03 13:33:01 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-01-09 11:49:35 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landesberg-2003" MODIFIED="2014-07-06 15:51:03 +0100" MODIFIED_BY="[Empty name]" NAME="Landesberg 2003" TYPE="JOURNAL_ARTICLE">
<AU>Landesberg G, Shatz V, Akopnik I, Wolf YG, Mayer M, Berlatzky Y, et al</AU>
<TI>Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>9</NO>
<PG>1547-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Le-Manach-2005" MODIFIED="2014-07-02 12:10:47 +0100" MODIFIED_BY="[Empty name]" NAME="Le Manach 2005" TYPE="JOURNAL_ARTICLE">
<AU>Le Manach YL, Perel A, Coriat P, Godet G, Bertrand M, Riou B</AU>
<TI>Early and delayed myocardial infarction after abdominal aortic surgery</TI>
<SO>Anesthesiology</SO>
<YR>2005</YR>
<VL>102</VL>
<PG>885-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nowygrod-2006" MODIFIED="2014-07-06 15:51:52 +0100" MODIFIED_BY="[Empty name]" NAME="Nowygrod 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nowygrod R, Egorova N, Greco G, Anderson P, Gelijns A, Moskowitz A, et al</AU>
<TI>Trends, complications and mortality in peripheral vascular surgery</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>2</NO>
<PG>205-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Priebe-2014" MODIFIED="2015-01-09 11:49:28 +0000" MODIFIED_BY="[Empty name]" NAME="Priebe 2014" TYPE="JOURNAL_ARTICLE">
<AU>Priebe HJ</AU>
<TI>The controversy of peri-operative B-blockade: what should I do?</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2014</YR>
<VL>47</VL>
<NO>2</NO>
<PG>119-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2015-01-09 11:49:17 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2006" MODIFIED="2015-01-09 11:49:24 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yang H, Raymer K, Butler R, Parlow J, Roberts R</AU>
<TI>The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial</TI>
<SO>American Heart Journal</SO>
<YR>2006</YR>
<VL>152</VL>
<NO>5</NO>
<PG>983-90</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2014-03-21 15:00:49 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MaVS-2006">
<CHAR_METHODS MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Study type: double-blind, randomised controlled trial</P>
<P>Study aim: to investigate the effects of metoprolol and its effects on cardiac complications at 30 days and 6 months after vascular surgery</P>
<P>Country: Canada</P>
<P>Setting: multicentre; 3 tertiary care centres</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomised: total n = 496 (metoprolol n = 246; placebo n = 250)</P>
<P>Age (mean (SD)): metoprolol = 66.4 (10.0) years; placebo = 65.9 (10.0) years</P>
<P>Gender (M/F): metoprolol = 193/53; placebo = 184/66</P>
<P>Inclusion criteria: American Society of Anesthesiology class III or less; undergoing abdominal aortic surgery and infrainguinal or axillofemoral re-vascularisation</P>
<P>Exclusion criteria: current or recent beta-adrenergic blocker use; current amiodarone use; airflow obstruction requiring treatment; history of CHF; history of atrioventricular block; previous adverse drug reactions to beta-adrenergic blockers; previous participation in the MaVS study</P>
<P>CVD risk factors: prior MI: metoprolol = 15.0%, placebo = 12.0%; angina: metoprolol = 7.3%, placebo = 10.0%; diabetes mellitus on treatment: metoprolol = 22.0%, placebo = 14.8%; permanent pacemaker: metoprolol = 0%, placebo = 0.4%</P>
<P>Type of vascular surgery: abdominal aortic surgery, infrainguinal or axillofemoral re-vascularisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: metoprolol; participants weighing &#8805; 75 kg received 100 mg, between 40 and 75 kg received 50 mg and &#8804; 40 kg received 25 mg, oral (twice daily) or intravenous route (every 6 hours)</P>
<P>Control: placebo; participants weighing &#8805; 75 kg received 100 mg, 40-75 kg received 50 mg and &#8804; 40 kg received 25 mg, oral or intravenous route</P>
<P>Duration: 2 hours preoperatively until hospital discharge or maximum of 5 days postoperatively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Postoperative 30-day composite incidence of non-fatal MI, unstable angina, new CHF, new atrial or ventricular dysrhythmia requiring treatment or cardiac death</P>
<P>The same composite outcome was evaluated over 6 months, but it should be noted that the outcome data between 1 and 6 months could not be used in the meta-analysis as the data were presented graphically with no numerical data</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>It should be noted that Figure 1 (of <LINK REF="REF-Yang-2006" TYPE="REFERENCE">Yang 2006</LINK>), which is a flow diagram of patient screening indicates that 497 participants were randomised (metoprolol n = 247; placebo n = 250), but as the n = 496 was used twice later in the text, we assumed this is the correct number randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-POBBLE-2005">
<CHAR_METHODS MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Study type: double-blind, randomised placebo-controlled trial</P>
<P>Study aim: to assess whether a policy of perioperative beta-adrenergic blockade with metoprolol reduced 30-day CV morbidity and mortality and reduced the length of hospital stay in people undergoing infrarenal vascular surgery</P>
<P>Country: UK</P>
<P>Setting: multicentre, vascular surgical units in 4 hospitals</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomised: total n = 103 (metoprolol n = 55; placebo n = 48)</P>
<P>Age (median (IQR)): metoprolol = 73 (61-79) years; placebo = 74 (66-76) years</P>
<P>Gender (M/F): total = 80/23; metoprolol = 40/13*; placebo = 35/9*, *6 participants did not undergo the procedure</P>
<P>Inclusion criteria: people undergoing major elective infrarenal vascular surgery under general anaesthesia</P>
<P>Exclusion criteria: already taking beta-adrenergic blockers; beta-adrenergic blockers could be dangerous; receiving current treatment for asthma; had aortic stenosis; had bradycardia or hypotension; perioperative beta-adrenergic blockade had already been shown to be beneficial; had unstable angina, or angina with positive dobutamine stress test; previous MI</P>
<P>CVD risk factors: current/ex smoker: metoprolol = 43%/47%, placebo = 10%/30%; diabetes: metoprolol = 19%, placebo = 18%</P>
<P>Type of vascular surgery: infrarenal; aortic aneurysm repair, aortoiliac grafts for stenosis, femofemoral cross-over grafts, femoropopliteal bypasses, femorodistal bypasses, amputation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: metoprolol; 2-4 mg in a slow intravenous injection over 5-10 minutes before intubation, then 50 mg twice daily, oral route</P>
<P>Control: placebo; equivalent 2-4 mg in a slow intravenous injection over 5-10 minutes before intubation, then 50 mg twice daily, oral route</P>
<P>Duration: 7 days after surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Fatal and non-fatal CV events within 30 days of surgery, myocardial ischaemia per 24 hours while wearing the Holter monitor, length of postoperative hospital stay, 2-year survival<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Study of average risk CV people undergoing vascular surgery, people with highest CV risk were excluded. All participants underwent a test dose of their allocated drug: metoprolol 50 mg or placebo equivalent for people weighing &gt; 55 kg and 25 mg for people weighing &#8804; 55 kg. People who did not tolerate the medication did not receive further beta-adrenergic blockade</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BP: blood pressure; HR: heart rate; IQR: interquartile range; CHF: congestive heart failure; CV: cardiovascular; CVD: cardiovascular disease; <BR/>F: female; M: male; MI: myocardial infarction; <BR/>n: number; SD: standard deviation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DECREASE-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>The principal investigator, Don Poldermans, of the DECREASE studies was dismissed by Erasmus University in Rotterdam for alleged scientific misconduct that included failing to obtain written patient consent and negligent data collection. Data from these trials cannot be relied upon as valid. The Erasmus Medical Center published a full copy of the report (<LINK REF="REF-Erasmus-MC-2012" TYPE="REFERENCE">Erasmus MC 2012</LINK>) which can be found here:</P>
<P>
<A HREF="http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en">http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en</A>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duranay-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes of the study (estimated glomerular filtration rate, serum creatinine and nitrate levels) were not within the scope of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Juul-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome data for people undergoing vascular surgery, separately, were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mangano-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome data for people undergoing vascular surgery, separately, were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-POISE-Trial-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome data for people undergoing vascular surgery, separately, were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ralley-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes of the study (haemodynamic outcomes) were not within the scope of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stone-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes of the study (myocardial ischaemia) were not within the scope of this review. If future data from the study is presented that includes outcome data relevant to our review, this study may be considered for inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suttner-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes of the study (myocardial ischaemia) were not within the scope of this review. If future data from the study is presented that includes outcome data relevant to our review, this study may be considered for inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zaugg-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome data for people undergoing vascular surgery, separately, were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-12-05 07:59:53 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MaVS-2006">
<DESCRIPTION>
<P>Quote: "Randomization was constructed in blocks of 4 by the study statistician&#8230;"</P>
<P>Comment: not enough information to determine adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-06 11:35:20 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-POBBLE-2005">
<DESCRIPTION>
<P>Quote: "Randomization as performed centrally at TheSealedEnvelope.com web site. Treatment was allocated in a 1:1 ratio by using random permuted blocks of size 2, 4, and 6 within four stratification factors..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-04 15:29:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MaVS-2006">
<DESCRIPTION>
<P>Insufficient description of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-POBBLE-2005">
<DESCRIPTION>
<P>Quote: "Randomization as performed centrally at TheSealedEnvelope.com web site"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-06-23 12:01:47 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:31:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MaVS-2006">
<DESCRIPTION>
<P>Quote: "The patients, investigators, and all caretakers were blinded to the study randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-POBBLE-2005">
<DESCRIPTION>
<P>Quote: "Trial drugs-metoprolol and placebo-of identical appearance were in gelatin-coated capsules or ampoules..."</P>
<P>Comment: study described as "double-blind". For safety reasons the anaesthesiologists administering the study drug were unblinded, but precautions were taken to ensure remaining clinicians and trial co-ordinators were blinded. There was no indication that blinding was broken for others involved in the trial, other than the anaesthesiologists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MaVS-2006">
<DESCRIPTION>
<P>Quote: "An independent adjudication committee reviewed all primary composite outcomes", ...."in a blinded fashion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-POBBLE-2005">
<DESCRIPTION>
<P>Study did not specify whether the outcome assessors were blinded or not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-09 11:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MaVS-2006">
<DESCRIPTION>
<P>Discontinuation was similar between treatment groups, and reasons were also similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:31:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-POBBLE-2005">
<DESCRIPTION>
<P>Drop-out rate was even between treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-07-01 14:31:28 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-04 15:30:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MaVS-2006">
<DESCRIPTION>
<P>All outcomes indicated in methods appear to be reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-POBBLE-2005">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-04 15:30:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MaVS-2006">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 11:48:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-POBBLE-2005">
<DESCRIPTION>
<P>Power calculations determined a study population of 300, but only 103 participants were recruited</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-01-12 08:39:03 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-01-12 08:39:03 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Beta-adrenergic blocker versus placebo</NAME>
<DICH_OUTCOME CHI2="2.9409936671334336" CI_END="15.019565932027271" CI_START="0.025967250215329706" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6245132718226202" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="65.99788666071174" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.1766573816661965" LOG_CI_START="-1.5855740372608347" LOG_EFFECT_SIZE="-0.20445832779731907" METHOD="MH" MODIFIED="2015-01-12 08:39:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08635775342596819" P_Q="1.0" P_Z="0.7717013555342471" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.497841891341793" TOTALS="YES" TOTAL_1="301" TOTAL_2="298" WEIGHT="100.00000000000001" Z="0.2901501706744694">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.074761429688909" CI_START="0.005950408965428278" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3169681657583256" LOG_CI_START="-2.2254531846369754" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2014-02-05 10:25:19 +0000" MODIFIED_BY="[Empty name]" ORDER="4583" O_E="0.0" SE="1.4934308864108556" STUDY_ID="STD-MaVS-2006" TOTAL_1="246" TOTAL_2="250" VAR="2.2303358124859143" WEIGHT="45.95987545843363"/>
<DICH_DATA CI_END="26.972250899498174" CI_START="0.2725927789934343" EFFECT_SIZE="2.7115384615384617" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4309171908889555" LOG_CI_START="-0.564485652847794" LOG_EFFECT_SIZE="0.4332157690205808" MODIFIED="2014-02-05 10:24:36 +0000" MODIFIED_BY="[Empty name]" ORDER="4580" O_E="0.0" SE="1.1721095078143438" STUDY_ID="STD-POBBLE-2005" TOTAL_1="55" TOTAL_2="48" VAR="1.3738406983087834" WEIGHT="54.040124541566385"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-01-06 12:00:19 +0000" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="246" TOTAL_2="250" WEIGHT="0.0" Z="0.0">
<NAME>Cardiovascular mortality</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.322216031430825" CI_START="0.01367809948165683" EFFECT_SIZE="0.3373901284651792" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9202389851940818" LOG_CI_START="-1.8639742419410867" LOG_EFFECT_SIZE="-0.47186762837350255" MODIFIED="2014-10-13 17:44:26 +0100" MODIFIED_BY="[Empty name]" ORDER="4585" O_E="0.0" SE="1.6354606316969469" STUDY_ID="STD-MaVS-2006" TOTAL_1="246" TOTAL_2="250" VAR="2.6747314778305764" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5426293681776508" CI_END="1.491736344949638" CI_START="0.45745828232836483" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8260793824127646" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" I2="0.0" I2_Q="100.0" ID="CMP-001.03" LOG_CI_END="0.1736920710911886" LOG_CI_START="-0.3396485050525789" LOG_EFFECT_SIZE="-0.08297821698069513" METHOD="MH" MODIFIED="2015-01-06 12:00:28 +0000" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.46134515705547907" P_Q="0.0" P_Z="0.5263215020348662" Q="8.472548928443824E-33" RANDOM="NO" SCALE="84.23" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="298" WEIGHT="100.0" Z="0.6336312551219977">
<NAME>Non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7434065551404183" CI_START="0.47784735689394725" EFFECT_SIZE="0.9127333752884413" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.24139867458297196" LOG_CI_START="-0.3207108118516221" LOG_EFFECT_SIZE="-0.039656068634325047" MODIFIED="2014-02-05 10:50:14 +0000" MODIFIED_BY="[Empty name]" ORDER="4589" O_E="0.0" SE="0.33018589481851374" STUDY_ID="STD-MaVS-2006" TOTAL_1="246" TOTAL_2="250" VAR="0.10902272513710261" WEIGHT="79.19869153059628"/>
<DICH_DATA CI_END="2.195492295448118" CI_START="0.11212457432150061" EFFECT_SIZE="0.49615384615384617" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3415319173911063" LOG_CI_START="-0.9502991927342441" LOG_EFFECT_SIZE="-0.304383637671569" ORDER="4586" O_E="0.0" SE="0.7588279887547579" STUDY_ID="STD-POBBLE-2005" TOTAL_1="55" TOTAL_2="48" VAR="0.575819916517591" WEIGHT="20.80130846940372"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-01-06 12:00:35 +0000" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="246" TOTAL_2="250" WEIGHT="0.0" Z="0.0">
<NAME>Arrhythmia</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8773233773855127" CI_START="0.2631986596679811" EFFECT_SIZE="0.702928870292887" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.27353908824074324" LOG_CI_START="-0.5797163266852929" LOG_EFFECT_SIZE="-0.15308861922227487" MODIFIED="2014-02-05 11:07:19 +0000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.5012064544099762" STUDY_ID="STD-MaVS-2006" TOTAL_1="246" TOTAL_2="250" VAR="0.2512079099422196" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-01-06 12:00:42 +0000" MODIFIED_BY="Anne Lawson" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="246" TOTAL_2="250" WEIGHT="0.0" Z="0.0">
<NAME>Heart failure</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.226329256099723" CI_START="0.4037751386987323" EFFECT_SIZE="1.7081604426002766" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8589177456141712" LOG_CI_START="-0.3938604250118638" LOG_EFFECT_SIZE="0.23252866030115368" MODIFIED="2014-02-05 11:07:35 +0000" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.7358880987776917" STUDY_ID="STD-MaVS-2006" TOTAL_1="246" TOTAL_2="250" VAR="0.5415312939226458" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-01-06 12:00:48 +0000" MODIFIED_BY="Anne Lawson" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="55" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.07981024629012" CI_START="0.10625298916039705" EFFECT_SIZE="2.669724770642202" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8265918254142854" LOG_CI_START="-0.9736588433237183" LOG_EFFECT_SIZE="0.42646649104528367" MODIFIED="2014-02-05 11:15:36 +0000" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="1.6448811042810687" STUDY_ID="STD-POBBLE-2005" TOTAL_1="55" TOTAL_2="48" VAR="2.7056338472209083" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.11047095090107323" CI_END="1.394709374010865" CI_START="0.5487510204680714" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8748418098404118" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.14448371985844666" LOG_CI_START="-0.26062465912660526" LOG_EFFECT_SIZE="-0.05807046963407929" METHOD="MH" MODIFIED="2015-01-06 12:00:54 +0000" MODIFIED_BY="Anne Lawson" NO="7" P_CHI2="0.7396086406478342" P_Q="1.0" P_Z="0.5741813643993066" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="298" WEIGHT="100.0" Z="0.5619040975319939">
<NAME>Composite cardiovascular events</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4561141385713845" CI_START="0.47260999641458273" EFFECT_SIZE="0.8295625942684767" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.16319541880180768" LOG_CI_START="-0.3254970966228662" LOG_EFFECT_SIZE="-0.08115083891052927" MODIFIED="2014-03-03 15:50:16 +0000" MODIFIED_BY="[Empty name]" ORDER="4599" O_E="0.0" SE="0.28706040262741905" STUDY_ID="STD-MaVS-2006" TOTAL_1="246" TOTAL_2="250" VAR="0.08240367475661593" WEIGHT="70.72109858017213"/>
<DICH_DATA CI_END="2.2715993465243285" CI_START="0.4264265886468589" EFFECT_SIZE="0.9842105263157894" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.35633173507704974" LOG_CI_START="-0.37015572390970974" LOG_EFFECT_SIZE="-0.006911994416330014" ORDER="4596" O_E="0.0" SE="0.42674232957974284" STUDY_ID="STD-POBBLE-2005" TOTAL_1="55" TOTAL_2="48" VAR="0.18210901585514588" WEIGHT="29.278901419827882"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9184926643791667" CI_END="7.648639139955182" CI_START="3.2248255251882747" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="4.9664400460975635" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.8835841715481088" LOG_CI_START="0.5085062226929188" LOG_EFFECT_SIZE="0.6960451971205138" METHOD="MH" MODIFIED="2015-01-06 12:01:00 +0000" MODIFIED_BY="Anne Lawson" NO="8" P_CHI2="0.3378711997551279" P_Q="1.0" P_Z="3.481009499543309E-13" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="298" WEIGHT="100.0" Z="7.274346690506134">
<NAME>Intra-operative bradycardia</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.2489669163872605" CI_START="2.7529718212803105" EFFECT_SIZE="4.467236467236467" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="26" LOG_CI_END="0.8602761176770188" LOG_CI_START="0.4398017660881723" LOG_EFFECT_SIZE="0.6500389418825956" MODIFIED="2014-02-05 10:28:46 +0000" MODIFIED_BY="[Empty name]" ORDER="4592" O_E="0.0" SE="0.24698871550489696" STUDY_ID="STD-MaVS-2006" TOTAL_1="246" TOTAL_2="250" VAR="0.06100342558675892" WEIGHT="83.88750957143189"/>
<DICH_DATA CI_END="19.808664686478" CI_START="2.8894643275845575" EFFECT_SIZE="7.565476190476191" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="7" LOG_CI_END="1.296855200483518" LOG_CI_START="0.46081733717277246" LOG_EFFECT_SIZE="0.8788362688281454" MODIFIED="2014-02-05 10:40:10 +0000" MODIFIED_BY="[Empty name]" ORDER="4590" O_E="0.0" SE="0.4910927793628996" STUDY_ID="STD-POBBLE-2005" TOTAL_1="55" TOTAL_2="48" VAR="0.24117211794237756" WEIGHT="16.112490428568115"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.428026690289854" CI_END="2.5915382447732123" CI_START="1.3085213683219252" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8414893890840762" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="118" I2="29.973297642145273" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.4135576223483879" LOG_CI_START="0.11678081911844947" LOG_EFFECT_SIZE="0.2651692207334187" METHOD="MH" MODIFIED="2015-01-06 12:01:06 +0000" MODIFIED_BY="Anne Lawson" NO="9" P_CHI2="0.23208700699819507" P_Q="1.0" P_Z="4.610100339640178E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="298" WEIGHT="99.99999999999999" Z="3.5024443742887765">
<NAME>Intra-operative hypotension</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.453299363459017" CI_START="1.1873230473699432" EFFECT_SIZE="1.7067099567099566" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="84" LOG_CI_END="0.3897505461540708" LOG_CI_START="0.07456889806352152" LOG_EFFECT_SIZE="0.23215972210879615" MODIFIED="2014-02-05 10:50:41 +0000" MODIFIED_BY="[Empty name]" ORDER="4595" O_E="0.0" SE="0.18513926026270885" STUDY_ID="STD-MaVS-2006" TOTAL_1="246" TOTAL_2="250" VAR="0.03427654569062305" WEIGHT="91.8613180958264"/>
<DICH_DATA CI_END="9.625634084208126" CI_START="1.1747854214548665" EFFECT_SIZE="3.3627450980392157" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="34" LOG_CI_END="0.983429348071677" LOG_CI_START="0.06995854849002871" LOG_EFFECT_SIZE="0.5266939482808529" MODIFIED="2014-02-05 10:36:52 +0000" MODIFIED_BY="[Empty name]" ORDER="4593" O_E="0.0" SE="0.536577269427644" STUDY_ID="STD-POBBLE-2005" TOTAL_1="55" TOTAL_2="48" VAR="0.28791516606642653" WEIGHT="8.138681904173582"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-01-06 12:01:12 +0000" MODIFIED_BY="Anne Lawson" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="246" TOTAL_2="250" WEIGHT="0.0" Z="0.0">
<NAME>Re-hospitalisation at 30 days</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5248945375669052" CI_START="0.48179979628183656" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.1832398087080242" LOG_CI_START="-0.31713338796925067" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-02-05 11:16:35 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.29392169261550155" STUDY_ID="STD-MaVS-2006" TOTAL_1="246" TOTAL_2="250" VAR="0.08638996138996138" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-01-12 08:38:54 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-01-12 08:38:54 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAAN1CAYAAABreRKnAABu20lEQVR42uydD4RVz///vyRJksjK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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-01-09 11:48:49 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAToAAAGRCAIAAAB6++gmAAARD0lEQVR42u3dwY5cxRXG8ZGQEAsv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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-01-09 10:57:17 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-01-09 10:57:17 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-10-06 20:40:42 +0100" MODIFIED_BY="Marlene Stewart">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-09 10:57:17 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="40">
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Surgical Procedures] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>12701</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [Reconstructive Surgical Procedures] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>623</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteries] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>1088</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MeSH descriptor: [Veins] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>714</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>(vascular or prosthetic or arterial or aort* or (lower near/3 limb) or vein or venous) near/3 (graft or reconstruct* or surgery or bypass or revascular*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>7485</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>MeSH descriptor: [Peripheral Vascular Diseases] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>133</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Diseases] this term only and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>29</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>MeSH descriptor: [Varicose Veins] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>250</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>MeSH descriptor: [Telangiectasis] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>MeSH descriptor: [Venous Insufficiency] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>76</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>MeSH descriptor: [Arterial Occlusive Diseases] this term only and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>228</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriolosclerosis] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis Obliterans] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>MeSH descriptor: [Atherosclerosis] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>37</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>MeSH descriptor: [Intermittent Claudication] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>61</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>MeSH descriptor: [Aortic Diseases] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>655</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>MeSH descriptor: [Aortic Aneurysm] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>590</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>MeSH descriptor: [Iliac Aneurysm] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>vascular near/2 surg*</P>
</TD>
<TD ALIGN="RIGHT">
<P>3086</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>(non-cardiac or noncardiac) near/2 surg*</P>
</TD>
<TD ALIGN="RIGHT">
<P>304</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>((abdominal near/3 aneury*) near/3 (graft or surg*))</P>
</TD>
<TD ALIGN="RIGHT">
<P>573</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>((lower near/3 extrem*) near/4 (obstruct* or occlus* or steno* or block* or obliter*) and (surgery or graft or bypass or revascula* or reconstruct*))</P>
</TD>
<TD ALIGN="RIGHT">
<P>94</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>((leg or limb) near/4 (obstruct* or occlus* or steno* or block* or obliter*) and (surgery or graft or bypass or revascula* or reconstruct*))</P>
</TD>
<TD ALIGN="RIGHT">
<P>259</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>(aort* or iliac or femoral or popliteal or femoropop* or fempop* or crural) near/3 (surg* or bypass or graft or reconstruct* or revascular*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>3327</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #21 or #22 or #23 or #24</P>
</TD>
<TD ALIGN="RIGHT">
<P>19560</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>MeSH descriptor: [Adrenergic beta-Antagonists] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>4188</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>(adrenergic near/3 (antagonist* or block*))</P>
</TD>
<TD ALIGN="RIGHT">
<P>7418</P>
</TD>
</TR>
<TR>
<TD>
<P>#28</P>
</TD>
<TD>
<P>(betablocker* or beta-blocker*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>4910</P>
</TD>
</TR>
<TR>
<TD>
<P>#29</P>
</TD>
<TD>
<P>(beta* near/3 block*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>8572</P>
</TD>
</TR>
<TR>
<TD>
<P>#30</P>
</TD>
<TD>
<P>acebutolol or atenolol or Tenormin or alprenolol</P>
</TD>
<TD ALIGN="RIGHT">
<P>3406</P>
</TD>
</TR>
<TR>
<TD>
<P>#31</P>
</TD>
<TD>
<P>betaxolol or bisoprolol or bupranolol</P>
</TD>
<TD ALIGN="RIGHT">
<P>1018</P>
</TD>
</TR>
<TR>
<TD>
<P>#32</P>
</TD>
<TD>
<P>carvedilol or Coreg or carteolol or celiprolol</P>
</TD>
<TD ALIGN="RIGHT">
<P>1227</P>
</TD>
</TR>
<TR>
<TD>
<P>#33</P>
</TD>
<TD>
<P>esmolol or labetalol or Normodyne or Trandate</P>
</TD>
<TD ALIGN="RIGHT">
<P>1004</P>
</TD>
</TR>
<TR>
<TD>
<P>#34</P>
</TD>
<TD>
<P>metoprolol or nadolol or nebivolol</P>
</TD>
<TD ALIGN="RIGHT">
<P>3075</P>
</TD>
</TR>
<TR>
<TD>
<P>#35</P>
</TD>
<TD>
<P>oxprenolol or penbutolol or pindolol</P>
</TD>
<TD ALIGN="RIGHT">
<P>1329</P>
</TD>
</TR>
<TR>
<TD>
<P>#36</P>
</TD>
<TD>
<P>Visken or practolol or propranolol or Inderal</P>
</TD>
<TD ALIGN="RIGHT">
<P>4564</P>
</TD>
</TR>
<TR>
<TD>
<P>#37</P>
</TD>
<TD>
<P>sotalol or timolol</P>
</TD>
<TD ALIGN="RIGHT">
<P>2269</P>
</TD>
</TR>
<TR>
<TD>
<P>#38</P>
</TD>
<TD>
<P>*lol</P>
</TD>
<TD ALIGN="RIGHT">
<P>15045</P>
</TD>
</TR>
<TR>
<TD>
<P>#39</P>
</TD>
<TD>
<P>#26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38</P>
</TD>
<TD ALIGN="RIGHT">
<P>19860</P>
</TD>
</TR>
<TR>
<TD>
<P>#40</P>
</TD>
<TD>
<P>#25 and #39 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>403</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies (4 records) included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;28 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;59 records screened by review authors&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;355 records screened by Trial Search Co-ordinator&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;355 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;403 records identified from CENTRAL&lt;/p&gt;&lt;p&gt;57 studies identified from Clinicaltrials.gov&lt;/p&gt;&lt;p&gt;5 records for 4 trilas from WHO&lt;/p&gt;&lt;p&gt;1 record from ISRCTN&lt;/p&gt;" WIDTH="148"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;52 records identified from Specialised Register&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;296 records not relevant&lt;/p&gt;" WIDTH="155"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;31 records not relevant&lt;/p&gt;" WIDTH="151"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9 studies (24 records) excluded, with reasons&lt;/p&gt;" WIDTH="153"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>